Intralesional Injection of Cystic HygromaUS: UltrasoundNCT07246928
Ultraspound-guided Intralesional Injection of Cystic Hygroma - A Case Report
A study testing Intralesional Injection of Bleomycin in people with Intralesional Injection of Cystic Hygroma and Cystic Hygroma (Macro-cystic Lymphatic Malformation), run by Delta University for Science and Technology at 1 site in Egypt.
Trial summary
Ultrasound-guided Intralesional Injection of Cystic Hygroma - A Case Report Read more about this study
- Who is it for?
- Ages 1 month to 12 years
- Conditions the study is for
- Intralesional Injection of Cystic Hygroma, Cystic Hygroma (Macro-cystic Lymphatic Malformation)
- What is being tested?
- Intralesional Injection of Bleomycin
- Type of treatment
- Injection or infusion, Surgery or procedure
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 1 participants
- Where
- 1 siteEgypt
- Study dates
- 1 Sep 2024to 6 Oct 2025
- Phase
- Interventional
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 month to 12 years
- All sexes
- No healthy volunteers
- Child
Who may be able to join
- Pediatric patients of age up to 12 years having cystic hygromas (macrocystic lymphatic malformations), from the vascular anomalies clinic at the pediatric surgery department in Cairo University Specialized Pediatric Hospital (Abu EL-Reesh hospital). -
Who cannot join
None listed.
Trial locations and contacts
1 site in 1 country.
Egypt1 site
Specialized Pediatric Hospital (Abu EL-Reesh Japanese hospital)
Cairo, Cairo Governorate, 12613
About this study
Official title: Ultrasound-guided Intralesional Injection of Cystic Hygroma - A Case Report
Ultrasound-guided Intralesional Injection of Cystic Hygroma - A Case Report
Read the detailed description
Ultrasound-guided Intralesional Injection of Cystic Hygroma [lymphatic malformation]
- Conditions
- Intralesional Injection of Cystic Hygroma, Cystic Hygroma (Macro-cystic Lymphatic Malformation)
- Being tested
- Intralesional Injection of Bleomycin
- Medical subject headings
- Lymphangioma, Cystic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Intralesional Injection of BleomycinProcedure or surgery
Aspiration of Cystic Hygroma Fluid and Intralesional Injection
| Study group | Role | What they receive |
|---|---|---|
| pediatric patient | Experimental | Not described Receives: Procedure: Intralesional Injection of Bleomycin |
What is being measured
The primary outcome is the main question the study is designed to answer.
improvement: change in lesion size
reduction in lesion size
Measured: one year
improvement: reduction of lesion size
Measured: one year
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted24 Nov 2025
- Study start1 Sep 2024
- Primary completion1 Sep 2025
- Study completion6 Oct 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Intralesional Injection of Cystic HygromaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Model description
- Case Report
- Masking
- None (open label)
- Enrolment
- 1 participants (actual)
Sponsor and investigators
- Lead sponsor
- Delta University for Science and Technology
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Sarah Arafat, Delta University for Science and Technology
- Investigators
- Gamal El-Tagy, MD, Study director, pediatric surgery department, Cairo University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07246928
- Sponsor's protocol ID
- 025091866
- Acronym
- US: Ultrasound
- Status last verified
- Oct 2025
- First submitted
- 19 Nov 2025
- Last updated
- 30 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Undecided
Study at a glance
From the registry record, last updated by the sponsor on 30 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Ultrasound-guided Intralesional Injection of Cystic Hygroma - A Case Report
- ClinicalTrials.gov ID
- NCT07246928
- Acronym / sponsor ID
- US: Ultrasound / 025091866
- Conditions
- Intralesional Injection of Cystic Hygroma, Cystic Hygroma (Macro-cystic Lymphatic Malformation)
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1 participants (actual)
- Lead sponsor
- Delta University for Science and TechnologyUniversity, hospital or other
- Study start
- 1 Sep 2024 (actual)
- Primary completion
- 1 Sep 2025 (actual)
- Study completion
- 6 Oct 2025 (actual)
- First posted
- 24 Nov 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Ultrasound-guided Intralesional Injection of Cystic Hygroma - A Case Report
Detailed description
Ultrasound-guided Intralesional Injection of Cystic Hygroma [lymphatic malformation]
Study design
- Primary purpose
- Treatment
- Allocation
- Not applicable
- Intervention model
- Single group
- Masking
- None (open label)
- Number of arms
- 1
- Model description
- Case Report
| Arm | Type | Receives |
|---|---|---|
| pediatric patient | Experimental | Procedure: Intralesional Injection of Bleomycin |
Who may qualify
- Ages
- 1 month to 12 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child
Key inclusion criteria (1 listed)
- Pediatric patients of age up to 12 years having cystic hygromas (macrocystic lymphatic malformations), from the vascular anomalies clinic at the pediatric surgery department in Cairo University Specialized Pediatric Hospital (Abu EL-Reesh hospital). -
Key exclusion criteria (0 listed)
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Intralesional Injection of BleomycinAspiration of Cystic Hygroma Fluid and Intralesional Injection | Procedure or surgery | pediatric patient |
Primary outcome
improvement: change in lesion size
Time frame: one year
reduction in lesion size
improvement: reduction of lesion size
Time frame: one year
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 30 Apr 2026.
- Role of Bleomycin Sclerotherapy as a Non-surgical Method for the Treatment of Cystic Hygroma of Head and Neck Region-an Institutional StudyLink provided by the sponsor.
- Individual participant dataSharing planned: Undecided
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Gamal El-Tagy, MD study director
pediatric surgery department, Cairo University
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Intralesional Injection of Bleomycin in people with Intralesional Injection of Cystic Hygroma and Cystic Hygroma (Macro-cystic Lymphatic Malformation), run by Delta University for Science and Technology at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 1 inclusion and 0 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 30 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
improvement: change in lesion size (time frame: one year). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 30 Apr 2026.